Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2025) 110 EP1341 | DOI: 10.1530/endoabs.110.EP1341

1Hospital Nacional Profesor Alejandro Posadas, Pediatric Endocrinology, El Palomar, Argentina; 2Hospital de Niños Ricardo Gutierrez, Pediatric Endocrinology, Buenos Aires, Argentina; 3Hospital Nacional Profesor Alejandro Posadas, Laboratory, El Palomar, Argentina; 4Hospital Nacional Profesor Alejandro Posadas, Adult Endocrinology, El Palomar, Argentina; 5Hospital Nacional Profesor Alejandro Posadas, Pediatric Hematology, Maternal and Child Department, El Palomar, Argentina; 6Hospital Nacional Alejandro Posadas, Pediatric Hemato-oncology, Buenos Aores, Argentina; 7Hospital Nacional Profesor Alejandro Posadas, Gynecology Surgical, El Palomar, Argentina; 8Hospital Nacional Profesor Alejandro Posadas, Obstetrics, Maternal and Child, El Palomar, Argentina; 9Hospital Nacional Profesor Alejandro Posadas, Medical Clinic, Maternal and Child Department, El Palomar, Argentina; 10Hospital Nacional Profesor Alejandro Posadas, ediatric Endocrinology Service, Maternal and Child Department, El Palomar, Argentina


JOINT3929

Introduction: Advances in cancer treatments have significantly improved the prognosis of pediatric cancers, with 5-year survival rates approaching 75-80%. However, fertility is affected in 8-12% of female survivors. Several studies suggest that cancer survivors have a similar likelihood of maintaining pregnancy beyond 20 weeks, but preterm birth rates are higher, with nearly 9% of babies born to mothers with cancer being premature (<37 weeks) compared to 6% in those without cancer treatment.

Objective: To evaluate the characteristics of pregnancies in patients undergoing oncological treatment in the childhood-juvenile stage.

Population and methods: Patients with a history of oncological disease in the childhood-juvenile stage treated at the Professor Alejandro Posadas National Hospital were studied, evaluated during the period from 11/01/2020 to 10/31/2022 by determining AMH, antral follicle count, and FSH determination. The participants were recruited during the follow-up of the long-term effects of cancer treatment. Descriptive statistics were presented.

Results: 71 pubertal and young adult patients were evaluated, 40 had the cancer diagnosis being prepubertal (56.3%) and 31 after having started puberty (43.7%). The median age at the start of cancer treatment was 8.1 years (0.9-17.6) and at the end of treatment was 10.1 years (2.1-20.3). The median of follow-up was 11.8 years (5-25) and at evaluation 19.9 years (10.8-31.9). The diagnosis was ALL in 59.2%, Hodgkin’s lymphoma in 11.3%, AML in 7% 53% received only chemotherapy treatment (CMT), 15.5% (CMT+RT); 15.5% (CMT + surgery). All participants who received BMT (8.4%) as part of their treatment had ovarian function and follicular reserve impairment. Thirteen patients had at least one pregnancy prior to evaluation, 3 of which became pregnant twice and 1 had a twin pregnancy. Of the 17 gestational products: 6 were TNB (4 AGA, 2 SGA), 8 PTNB (4 AGA, 4 SGA), 2 spontaneous abortions (9 and 11 weeks), and 1 legal pregnancy interruption (12 weeks). The age of the first pregnancy was 18.8 (15.2-23) years. 18.3% managed to conceive without using assisted reproduction techniques. Two of the patients who subsequently became pregnant had AMH values < 1 ng/ml and none of the patients who achieved pregnancy had FSH values ≥25 IU/L.

Conclusion: In our study, 18.3% of cancer survivors had a recorded pregnancy. Patients would benefit from more frequent obstetric monitoring to reduce the risk of possible gestational complications.

Volume 110

Joint Congress of the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE) 2025: Connecting Endocrinology Across the Life Course

European Society of Endocrinology 
European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches